Solid Tumor Therapeutics Market - By Drug Class (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics), Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, mTOR Inhibitors, PARP Inhibitors, Proteasome Inhibitors), Immunotherapy (Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Therapy), Hormone Therapy (Anti-estrogens, Anti-androgens, Aromatase Inhibitors), Others), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Pancreatic Cancer, Liver Cancer, Ovarian Cancer, Bladder Cancer, Gastric Cancer, Kidney Cancer, Head and Neck Cancer, Others), By Treatment Modality (Surgical, Radiation Therapy, Systemic Therapy (Monotherapy, Combination Therapy)), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Homecare Settings), and By Country (Japan, China, India, South Korea, Australia & NZ, ASEAN, Rest of Asia-Pacific)

$2400.00